Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer

Fulvestrant 500 mg is standard of care for endocrine therapy‐naive or pretreated women with hormone receptor‐positive (HR+) metastatic breast cancer (MBC). This study was conducted to explore the potential factors and duration of last endocrine therapy as predictors for the efficacy of fulvestrant 5...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Zhao, Yannan, Li, Yi, Gong, Chengcheng, Xie, Yizhao, Zhang, Jian, Wang, Leiping, Cao, Jun, Tao, Zhonghua, Wang, Biyun, Hu, Xichun
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724295/
https://ncbi.nlm.nih.gov/pubmed/33022852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3491
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars